Sheila Crispin
Acute Care · Stayton, ORNPI 1679040026
Payments from drug & device makers
What this record shows
Inspire Medical Systems, Inc. accounts for 66.4% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $1,581, more than ten times the $34 reported in 2022. Among acute care clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 44 payments — averaging $46.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$140
- GSK$65
- Insmed, Inc.$62
- Amgen$59
- Novo Nordisk$42
- plus $319 from 12 others
What the payments were for
- Travel & lodging$1,03651%
- Food & beverage$1,00849%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 17 | $1,357 |
| Regeneron Healthcare Solutions, Inc. | 2 | $140 |
| GSK | 3 | $65 |
| Insmed, Inc. | 3 | $62 |
| Amgen | 3 | $59 |
| Novo Nordisk | 2 | $42 |
| Pfizer | 2 | $41 |
| United Therapeutics Corporation | 2 | $38 |
| Fisher & Paykel Healthcare Inc | 1 | $37 |
| Verona Pharma, Inc. | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 1 | $30 |
| Lilly USA, LLC | 1 | $25 |
| Grifols USA, LLC | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| AstraZeneca | 1 | $19 |
| Bayer | 1 | $18 |
| Baxter Healthcare | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,044 in reported general payments places this provider in the 90th percentile of 105 acute care providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 506 | $427,177 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 185 | $137,533 |
| XolairOmalizumab | 28 | $95,018 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 116 | $57,508 |
| Dupixent PenDupilumab | 15 | $54,573 |
| Spiriva RespimatTiotropium Bromide | 59 | $39,209 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $36,390 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 57 | $31,898 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 20 | $11,240 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 391 | $10,883 |
| Roflumilast | 118 | $10,825 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 67 | $10,592 |
| Advair HfaFluticasone Propion/Salmeterol | 24 | $9,675 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $7,709 |
| XareltoRivaroxaban | 13 | $7,424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $65 | $528,785709 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere | $19 | $148,772205 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 105 acute care providers in Oregon.
Other acute care in Stayton
- Robin MillerPortland$74K
- Jacqueline TrussellPortland$15K
- Lina Rossetti-GrulichPortland$8K
- Drury HallBend$5K
- Carla CochranMedford$4K
- Nicole TabbalWilsonville$3K
- Aura PetcuPortland$3K
- Jamie FungPortland$2K
- Amanda EckersleyCorvallis$2K
- Jill KleinerTigard$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.